Currently out of the existing stock ratings of Pete Stavropoulos, 26 are a BUY (100%).

Pete Stavropoulos

Work Performance Price Targets & Ratings Chart

Analyst Pete Stavropoulos, currently employed at CANTOR FITZGERALD, carries an average stock price target met ratio of 38.33% that have a potential upside of 103.51% achieved within 194 days.

Pete Stavropoulos’s has documented 47 price targets and ratings displayed on 6 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on ANNX, Annexon  at 15-Nov-2024.

Wall Street Analyst Pete Stavropoulos

Analyst best performing recommendations are on ORTX (ORCHARD THERAPEUTICS PLC).
The best stock recommendation documented was for ORTX (ORCHARD THERAPEUTICS PLC) at 6/27/2023. The price target of $15 was fulfilled within 100 days with a profit of $9.77 (186.81%) receiving and performance score of 18.68.

Average potential price target upside

ANNX Annexon  PLRX Pliant Therapeutics  ARCT Arcturus Therapeutics Holdings ORTX Orchard Therapeutics PLC RZLT Rezolute ABOS Acumen Pharmaceuticals

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

$16

$11.58 (261.99%)

$16

29 days ago
(15-Nov-2024)

0/11 (0%)

$9.83 (159.32%)

Buy

$30

$25.58 (578.73%)

$30

29 days ago
(15-Nov-2024)

0/7 (0%)

$23.83 (386.22%)

Buy

$13

$8.58 (194.12%)

$11

8 months 13 days ago
(01-Apr-2024)

1/4 (25%)

$6.37 (96.08%)

188

Buy

$10

$5.58 (126.24%)

$6

8 months 16 days ago
(28-Mar-2024)

4/5 (80%)

$2.83 (39.47%)

106

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

Which stock is Pete Stavropoulos is most bullish on?

Potential upside of $0 has been obtained for ARCT (ARCTURUS THERAPEUTICS HOLDINGS)

Which stock is Pete Stavropoulos is most reserved on?

Potential downside of -$0 has been obtained for ANNX (ANNEXON )

What Year was the first public recommendation made by Pete Stavropoulos?

On 2021

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?